Can Testosterone Cause Hair Loss in Females?

The relationship between testosterone and female hair loss is far more complicated than the simple “high testosterone equals thinning hair” story you’ll find repeated online. While androgens do play a role in many cases of female pattern hair loss, the connection is not straightforward: many women with thinning hair have perfectly normal testosterone levels, and some research suggests testosterone therapy can actually improve scalp hair growth in certain women. The real picture involves a web of hormonal interactions, genetics, and metabolic factors that make female hair loss a genuinely different condition from its male counterpart.

Female Hair Loss Looks and Acts Differently Than Male Hair Loss

Male pattern baldness follows a recognizable script: a receding hairline, a thinning crown, and an eventual merging of the two into the horseshoe pattern most people picture. Female pattern hair loss (FPHL) takes a different path. Women typically experience diffuse thinning across the top of the scalp, often with a widening part line, but the frontal hairline usually stays intact. Complete baldness is rare in women unless there’s an underlying inflammatory or scarring condition involved.¹

One reason for the preserved hairline in women is an enzyme called aromatase, which is more active in the frontal scalp of females. Aromatase converts testosterone into estradiol, a form of estrogen, essentially neutralizing the androgen before it can shrink the hair follicle. Men have far less aromatase activity in those same areas, which is why their hairlines are so vulnerable.¹

Three-dimensional reconstructions of the tiny muscles attached to hair follicles have also helped explain why female thinning looks so different. In women with FPHL, the attachment between the stem cell population in the follicle bulge and the arrector pili muscle is disrupted in a pattern that leads to diffuse miniaturization rather than the patchy retreat seen in men.²

The Surprising Disconnect Between Testosterone and Female Hair Loss

Here is where the common narrative breaks down. If testosterone were the primary driver of FPHL, you’d expect women with thinning hair to reliably show elevated testosterone on blood tests. They often don’t. A study evaluating hormone levels in female patients with pattern hair loss found that sex hormone concentrations did not correlate with reported symptoms, and even among patients who showed outward signs suggestive of hormonal excess, no significant abnormalities turned up on hormone panels.³

Another study specifically measuring testosterone and DHEAS (another androgen produced by the adrenal glands) in women with FPHL and acne found no significant statistical correlation between those hormone levels and the severity of hair loss. In fact, a majority of patients with FPHL had low total testosterone, a finding that ran counter to what the researchers had expected based on previous literature.⁴

This disconnect is substantial enough that some researchers now argue female pattern hair loss can develop entirely in the absence of elevated androgens. Female hormone cycles appear to mask androgenic effects and prevent the classic clinical signs associated with androgen-driven balding in men.¹

When Testosterone Therapy Improves Hair Growth

Perhaps the most counterintuitive finding in this area comes from women receiving testosterone therapy for androgen deficiency. In a questionnaire study of 285 women treated with subcutaneous testosterone, not a single patient reported scalp hair loss as a side effect of treatment. Among the 76 women who had already been experiencing hair thinning before starting therapy, nearly two-thirds reported hair regrowth while on testosterone.⁵

The researchers proposed that this improvement was due to an anabolic effect of testosterone on hair growth and explicitly stated that the absence of any hair loss complaints “casts doubt on the presumed role of testosterone in driving female scalp hair loss.”⁶

This doesn’t mean testosterone therapy is risk-free for hair in all women. The dose, route of administration, and an individual’s genetic sensitivity to androgens all matter. But the finding that physiologic-dose testosterone can help rather than hurt scalp hair challenges the blanket assumption that testosterone and female hair loss always travel together.

What Matters More Than Testosterone Itself

If raw testosterone levels don’t predict female hair loss well, what does? The answer increasingly points to a protein called sex hormone-binding globulin (SHBG). SHBG circulates in the blood and binds to testosterone, making it biologically inactive. When SHBG is low, a larger fraction of testosterone is “free” and available to act on tissues, including hair follicles, even if total testosterone is normal.

Early research from the 1980s found that young women with diffuse hair loss had significantly lower SHBG levels compared to controls, while their testosterone levels were normal.⁷ More recent work has confirmed this: in female patients with androgenetic alopecia, higher SHBG was associated with better hair density and a lower proportion of miniaturized hairs, while lower SHBG tracked with more severe loss.⁸

This explains why conditions that lower SHBG, like insulin resistance, obesity, and polycystic ovary syndrome, are so consistently linked to female hair thinning. It also explains why a standard testosterone blood test can come back “normal” while the hair is still responding to androgen stimulation. The total amount of testosterone isn’t the whole story; how much of it is freely circulating and how sensitive the follicles are to it both matter.

PCOS and the Androgen Connection

Polycystic ovary syndrome is the condition that comes closest to the “testosterone causes female hair loss” narrative being literally true. Women with PCOS often have elevated androgens, irregular cycles, and metabolic disturbances that collectively push hair follicles toward miniaturization. A systematic review and meta-analysis estimated the pooled prevalence of female pattern hair loss in PCOS patients at about 28%.⁹

That number is worth sitting with. It means roughly three in ten women with PCOS experience noticeable pattern hair loss, but it also means the majority do not. Even in a condition defined partly by androgen excess, hair thinning is far from universal, reinforcing the idea that androgens alone aren’t sufficient to trigger FPHL. Individual follicle sensitivity, local enzyme activity, and other hormonal and metabolic factors all modulate whether excess androgens translate into visible thinning.

The psychological burden for those who do lose hair is real. In one study of teenage girls with PCOS, over 60% reported psychological distress related to hair loss, with low self-esteem, social avoidance, and embarrassment reported frequently, particularly among those with more noticeable scalp changes.¹⁰ Depression symptoms and reduced quality of life are documented across multiple studies of women with FPHL, whether or not PCOS is the underlying cause.⁹

Menopause and the Estrogen Drop

If PCOS represents the high-androgen scenario, menopause illustrates the flip side: what happens when estrogen falls away. During menopause, estrogen levels decline while androgens remain relatively stable, shifting the hormonal ratio in a direction that unmasks androgenic effects on the scalp. This is a common trigger for women who notice their hair thinning in their late forties or fifties.¹¹

The aromatase buffer described earlier becomes less effective as overall estrogen production declines. Changes in hair texture, loss of volume, and a shift from terminal (thick) hairs to finer vellus hairs are all part of the picture. Importantly, the hair loss women experience after menopause is attributed primarily to the decrease in estrogen, not to a surge in testosterone. The testosterone was always there; it’s the protective counterbalance that weakened.

The Genetics Tell a Different Story Too

Male pattern baldness has a well-established genetic link to the androgen receptor gene on the X chromosome. Researchers naturally looked for the same association in women and came up empty. A study of Egyptian women with pattern hair loss found no association between the androgen receptor gene and female androgenetic alopecia, concluding that this gene “does not serve as a biomarker for the identification of women with a predisposition to AGA.”¹²

A broader review confirmed this pattern: while the phenotype of follicular miniaturization looks similar in men and women, the genetic factors that cause male pattern hair loss don’t account for the same phenotype in females. Different genes appear to be contributing to FPHL, though exactly which ones remains an active area of investigation.¹³

This genetic divergence is one more piece of evidence that female hair loss is not simply a milder version of male hair loss. It appears to be a related but distinct condition with its own biological architecture.

Conditions That Mimic Hormonal Hair Loss

Not all diffuse hair thinning in women is FPHL. The most common look-alike is chronic telogen effluvium (CTE), a condition where an abnormally high number of hairs shift into their shedding phase at once. CTE can be triggered by stress, nutritional deficiencies, thyroid dysfunction, or medications, and it produces generalized thinning that can closely resemble the early stages of pattern hair loss. The distinction matters because CTE is typically reversible once the trigger is addressed, while FPHL is progressive.¹⁴

Other conditions in the differential include frontal fibrosing alopecia, a scarring form of hair loss that is becoming more frequently diagnosed in postmenopausal women, and alopecia areata incognito, an autoimmune condition that can present as diffuse loss rather than the typical round patches.¹⁵ Some women have FPHL and CTE simultaneously, making diagnosis even trickier.¹⁶

The practical point: if you’re experiencing hair thinning, jumping straight to “it must be my hormones” can lead you down the wrong treatment path. A dermatologist can distinguish between these conditions using trichoscopy (magnified scalp examination) and sometimes a simple hair-shedding analysis, and the treatment differs significantly depending on what’s actually going on.

Treatment Options That Work

Minoxidil remains the best-studied topical treatment for FPHL. In a randomized trial, both 2% and 5% topical minoxidil were superior to placebo after 48 weeks, with the 5% solution showing the best results across hair count, investigator assessment, and patient-reported outcomes.¹⁷ For women who struggle with twice-daily application or scalp irritation from the topical form, low-dose oral minoxidil has emerged as an alternative that appears effective and well-tolerated in healthy patients.¹⁸

Spironolactone, an anti-androgen that blocks testosterone’s effects at the receptor level, is commonly prescribed off-label for FPHL. A systematic review of four studies found that roughly 57% of women treated with spironolactone showed improvement in hair loss, with combined therapy (spironolactone plus another agent) performing better than spironolactone alone.¹⁹ A randomized pilot trial in premenopausal women found that clinically meaningful improvement occurred in about 38% of those on spironolactone compared to 9% on placebo.²⁰

A study looking more broadly at oral antiandrogens found that about 44% of women had regrowth and another 44% saw their hair loss stabilize, meaning that roughly nine in ten women treated could expect at minimum to stop getting worse.²¹ Spironolactone does carry side effects including menstrual irregularities and breast tenderness, and it cannot be used during pregnancy due to the risk of feminizing a male fetus.

Platelet-rich plasma (PRP) injections are gaining traction as a non-hormonal option. A randomized controlled trial found that 57% of women receiving PRP showed improvement on blinded photographic assessment at 24 weeks, compared to 7% in the placebo group. Hair density increased by about 106 hairs per square centimeter in the PRP group while decreasing in the placebo group.²² The trade-offs are cost, the need for repeat sessions, and minor procedural discomfort.

Metabolic Health as an Overlooked Factor

The connection between metabolic syndrome and female hair loss is underappreciated. A cross-sectional study in western India found that about a third of women with FPHL met criteria for metabolic syndrome, and its presence was significantly correlated with both earlier onset of hair loss and more severe thinning.²³

This connection makes biological sense given the role of SHBG discussed earlier. Insulin resistance, which is central to metabolic syndrome, drives SHBG levels down, freeing up more testosterone to act on tissues. It also promotes low-grade systemic inflammation, which emerging research suggests may independently harm hair follicles. Addressing metabolic health through diet, exercise, and weight management may therefore have benefits for hair that go beyond what you’d expect from a “hair loss treatment” alone.

The Scalp Microbiome Angle

An emerging and genuinely surprising line of research points to the community of bacteria and fungi living on the scalp as a potential modifier of androgenetic alopecia. Studies comparing people with and without hair loss have found differences in microbial diversity, with the most consistent finding being an enrichment of certain bacteria in people with AGA.²⁴ A Korean cross-sectional study found that as hair loss progressed, the scalp showed increasing colonization by non-resident bacteria, suggesting a disruption of the normal microbial balance.²⁵

These microbial shifts appear to parallel changes in scalp oil composition. Certain bacteria and fungi that thrive on altered lipids can activate inflammatory pathways, potentially contributing to the follicle miniaturization that drives visible thinning.²⁴ Research in young Chinese women with oily scalps has also linked abnormalities in scalp lipid metabolism and microbiological changes to hair loss.²⁶

The evidence here is still preliminary and inconsistent across studies, and nobody is suggesting that scalp bacteria cause hair loss in the same direct way that, say, a fungal infection causes ringworm. But it opens the door to interventions like antifungal shampoos containing ketoconazole or other agents that target the scalp environment rather than hormones, which could be especially relevant for women who don’t want to take systemic medications. It’s one more reminder that female hair loss is a multi-layered problem, and testosterone is just one thread in a much more tangled story.